|
English
|
正體中文
|
简体中文
|
2826208
|
|
???header.visitor??? :
31904756
???header.onlineuser??? :
1475
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"fox t"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-10-22T07:27:55Z |
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
|
Fox T.; Papavassilis C.; Huang J.; Gong Y.; TSEN-FANG TSAI; Blauvelt A.; Leonardi C.L.; Griffiths C.E.M.; Reich K.; Van De Kerkhof P.C.M. |
| 臺大學術典藏 |
2017 |
Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections
|
Kamm?ller M.; TSEN-FANG TSAI; Griffiths C.E.M.; Kapoor N.; Kolattukudy P.E.; Brees D.; Chibout S.-D.; Safi J.; Jr.; Fox T. |
| 國立臺灣大學 |
2016 |
Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: Pooled analysis of 10 phase 2/3 studies
|
Foley, P.; Griffiths, C.; Reich, K.; Leonardi, C. L.; Blauvelt, A.; Mehta, N. N.; Tsai, T. F.; Gong, Y.; Papavassilis, C.; Huang, J.; Fox, T.; van de Kerkhof, P.; 蔡呈芳 |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
